This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics.
More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PAD.
The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others.
The PAD pipeline mainly includes receptor agonists, followed by biological factor activators and enzyme inhibitors.
The majority of Phase III trials were backed by commercial sponsors, academic sponsors mostly conducted Phase II trials.
In deals involving companies developing PAD assets that occurred during past 10 years, Partnerships and acquisitions were the most prevalent deal type in North America, acquisitions dominated in Europe and Asia-Pacific.
Scope
GlobalData’s PAD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the PAD market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Report Scope
Key Findings
Disease Overview
Disease Etiology (1/2)
Epidemiology Overview
Epidemiology Overview - Diagnosed Prevalent Cases of PAD in 2023 and 2024
Treatment Overview
Treatment Guidelines
Treatment Algorithm - Choice of Antithrombotic Therapy in PAD
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in PAD
Marketed Drugs - Overview by Mechanism of Action
Marketed Drugs - Overview by Route of Administration
Marketed Drugs - Overview by Molecule Type
Marketed Drug Profile - Bayer's Xarelto
Marketed Drug Profile - Merck's Zontivity
Marketed Drug Profile - AnGes's Collategene
Marketed Drug Profile - Artgen Biotech's Neovasculgen
Marketed Drug Profile - Sihuan Pharmaceutical's Anjieli
Marketed Drug Profile - Libbs Farmaceutica's Cebralat
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Cost of Therapy
Marketed Drugs - Time to Pricing and Reimbursement for Xarelto
Pipeline Drugs Assessment
Pipeline Drugs Overview - Late-Stage Pipeline Drugs in PAD
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Route of Administration
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in PAD
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Cardiovascular and PAD
Clinical Trials Assessment
Clinical Trials in PAD - Historical Overview
Clinical Trials in PAD - Overview by Phase
Clinical Trials in PAD - Overview by Status
Clinical Trials in PAD - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in PAD - Trials with a Virtual Component
Clinical Trials in PAD - Geographic Overview
Clinical Trials in PAD - Single-Country and Multinational Trials by Region
Clinical Trials in PAD - Top Sponsors with Breakdown by Phase
Clinical Trials in PAD - Top Sponsors with Breakdown by Status
Clinical Trials in PAD - Overview by Endpoint Status
Clinical Trials in PAD - Overview by Race and Ethnicity
Clinical Trials in PAD - Enrollment Data
Clinical Trials in PAD - Overview of Sites by Geography
Clinical Trials in PAD - Top 20 Countries for Trial Sites